Showing 1 - 5 results of 5 for search 'Hemant Murthy', query time: 0.03s Refine Results
  1. 1
    Corrigendum to “Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features”

    Corrigendum to “Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features” by Abdullah M. Khan, Jameel Muzaffar, Hemant Murthy, John R. Wingard, Jan S. Moreb

    Published 2019-01-01
    Get full text
    Article
  2. 2
    Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy

    Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy by Santiago Mercadal, Kwang Woo Ahn, Mariam Allbee-Johnson, Siddhartha Ganguly, Praveen Ramakrishnan Geethakumari, Sanghee Hong, Adriana Malone, Hemant Murthy, Attaphol Pawarode, Alejandro R. Sica, Melhem Solh, Celalettin Ustun, Mazyar Shadman, Craig S. Sauter, Mehdi Hamadani, Alex F. Herrera, Catherine J. Lee

    Published 2024-09-01
    Get full text
    Article
  3. 3
    U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity

    U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity by Talha Badar, Yenny A. Moreno Vanegas, Ahmad Nanaa, James M. Foran, Aref Al-Kali, Abhishek Mangaonkar, Hemant Murthy, Hassan B. Alkhateeb, David Viswanatha, Rong He, Mithun Shah, Cecilia Arana Yi, Mark R. Litzow, Naseema Gangat, Ayalew Tefferi, Mrinal M. Patnaik

    Published 2023-09-01
    Get full text
    Article
  4. 4
    Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent

    Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent by Nickolas Steinauer, Kristen McCullough, Aref Al-Kali, Hassan B. Alkhateeb, Kebede H. Begna, Abhishek A. Mangaonkar, Antoine N. Saliba, Mehrdad Torghabeh, Mark R. Litzow, William J. Hogan, Mithun Shah, Mrinal M. Patnaik, Animesh Pardanani, Talha Badar, Hemant Murthy, James Foran, Cecilia Arana Yi, Ayalew Tefferi, Naseema Gangat

    Published 2024-03-01
    Get full text
    Article
  5. 5
    Genetic landscape and clinical outcomes of patients with <i>BCOR</i> mutated myeloid neoplasms

    Genetic landscape and clinical outcomes of patients with <i>BCOR</i> mutated myeloid neoplasms by Anmol Baranwal, Mark Gurney, Rami Basmaci, Bahga Katamesh, Rong He, David S. Viswanatha, Patricia Greipp, James Foran, Talha Badar, Hemant Murthy, Cecilia Arana Yi, Jeanne Palmer, Abhishek A. Mangaonkar, Mrinal M. Patnaik, Mark R. Litzow, William J. Hogan, Kebede Begna, Naseema Gangat, Ayalew Tefferi, Aref Al-Kali, Mithun V. Shah, Hassan B. Alkhateeb

    Published 2024-02-01
    Get full text
    Article

Search Tools: